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Abstract
Introduction: Autoantibodies have a central role in systemic lupus erythematosus (SLE). The presence of
autoantibodies preceding disease onset by years has been reported both in patients with SLE and in those with
rheumatoid arthritis, suggesting a gradual development of these diseases. Therefore, we sought to identify
autoantibodies in a northern European population predating the onset of symptoms of SLE and their relationship
to presenting symptoms.
Methods: The register of patients fulfilling the American College of Rheumatology criteria for SLE and with a given
date of the onset of symptoms was coanalysed with the register of the Medical Biobank, Umeå, Sweden. Thirty-
eight patients were identified as having donated blood samples prior to symptom onset. A nested case-control
study (1:4) was performed with 152 age- and sex-matched controls identified from within the Medical Biobank
register (Umeå, Sweden). Antibodies against anti-Sjögren’s syndrome antigen A (Ro/SSA; 52 and 60 kDa), anti-
Sjögren’s syndrome antigen B, anti-Smith antibody, ribonucleoprotein, scleroderma, anti-histidyl-tRNA synthetase
antibody, double-stranded DNA (dsDNA), centromere protein B and histones were analysed using the AtheNA
Multi-Lyte ANA II Plus Test System on a Bio-Plex Array Reader (Luminex
200). Antinuclear antibodies test II (ANA II)
results were analysed using indirect immunofluorescence on human epidermal 2 cells at a sample dilution of 1:100.
Results: Autoantibodies against nuclear antigens were detected a mean (±SD) of 5.6 ± 4.7 years before the onset
of symptoms and 8.7 ± 5.6 years before diagnosis in 63% of the individuals who subsequently developed SLE. The
sensitivity (45.7%) was highest for ANA II, with a specificity of 95%, followed by anti-dsDNA and anti-Ro/SSA
antibodies, both with sensitivities of 20.0% at specificities of 98.7% and 97.4%, respectively. The odds ratios (ORs)
for predicting disease were 18.13 for anti-dsDNA (95% confidence interval (95% CI), 3.58 to 91.84) and 11.5 (95% CI,
4.54 to 28.87) for ANA. Anti-Ro/SSA antibodies appeared first at a mean of 6.6 ± 2.5 years prior to symptom onset.
The mean number of autoantibodies in prediseased individuals was 1.4, and after disease onset it was 3.1 (P <
0.0005). The time predating disease was shorter and the number of autoantibodies was greater in those individuals
with serositis as a presenting symptom in comparison to those with arthritis and skin manifestations as the
presenting symptoms.
Conclusions: Autoantibodies against nuclear antigens were detected in individuals who developed SLE several
years before the onset of symptoms and diagnosis. The most sensitive autoantibodies were ANA, Ro/SSA and
dsDNA, with the highest predictive OR being for anti-dsDNA antibodies. The first autoantibodies detected were
anti-Ro/SSA.
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Systemic lupus erythematosus (SLE) is a heterogeneous
disease with diverse clinical manifestations and variable
severity in individual patients and between different
patient populations [1,2]. A typical pathophysiological
sign in SLE patients is the production of autoantibodies
directed against nuclear antigens, which precede the
development of clinical manifestations [3,4]. In particu-
lar, antibodies against double-stranded DNA (anti-
dsDNA) have been shown to increase just prior to a
diagnosis of SLE [5]. Individuals who develop SLE have
also been found to gradually fulfill the clinical classifica-
tion criteria that are preceded by the appearance of
associated autoantibodies before diagnosis [6]. Further-
more, in patients defined as having undifferentiated con-
nective tissue disease, a diagnosis of SLE was predicted
in a 5-year follow-up study on the basis of the presence
of anti-dsDNA antibodies [7].
There are several autoimmune diseases that are recog-
nised by exhibiting a long preclinical phase during
which susceptible individuals who later develop disease
can be identified by the presence of autoantibodies
[8-11]. The development of a rheumatic disease in
asymptomatic mothers expressing anti-Sjögren’ss y n -
drome antigen A (Ro/SSA) and/or anti-Sjögren’ss y n -
drome antigen B (La/SSB) antibodies, and identified by
the birth of a child with a congenital heart block, was
found to be relatively common at 48% [12]. In another
study, the detection of anti-La/SSB antibodies predated
clinical evidence of Sjögren’ss y n d r o m eb ym o n t h sa n d
in some cases by years [13]. Furthermore, in an animal
model of SLE, mice immunized with human Ro/SSA
developed autoimmunity not only towards this molecule
but also towards other immunologically similar mole-
cules in a process equivalent to epitope spreading [14].
T h ep r e s e n c eo fa n t i n u c l e a ra n t i b o d i e s( A N A s )w a s
shown to predate the development of SLE in a small
study conducted in Finland [15]. In the study by
Arbuckle et al. [3], the frequency of producing at least
one SLE-related autoantibody years before diagnosis was
high at 88%. ANAs were present in 78% of the cases,
anti-dsDNA antibodies were present in 55% and anti-
Ro/SSA antibodies were present in 47%. Furthermore,
the appearance of these antibodies appeared to follow a
predictable course [3]. Anticardiolipin antibodies have
been found to precede both the diagnosis of SLE and
the development of clinical manifestations of thrombosis
by a number of years [16].
The aim of this study was to analyse, using multiplex
technology, the autoantibodies predating the onset of
symptoms of SLE in individuals in a patient population
in northern Europe and to relate these autoantibodies to
the first recorded symptom of disease.
Materials and methods
Patients and controls
The register of patients with SLE attending the Depart-
ment of Rheumatology, University Hospital, Umeå, Swe-
den, with a known date of the onset of symptoms was
coanalysed with the registers of the Medical Biobank
(Umeå, Sweden) and of the maternity cohort (that is,
the record of samples obtained for rubella screening of
pregnant women) from northern Sweden. All SLE
patients had been evaluated clinically. A total of 38
patients (3 male and 35 female, of whom 37 fulfilled
four and one fulfilled only three of the American Col-
lege of Rheumatology (ACR) criteria for SLE [17,18])
were identified as having donated blood before the
onset of any symptoms of disease. One of the patients
also fulfilled the criteria for mixed connective tissue dis-
ease [19]. Nineteen of the patients were identified from
the Medical Biobank (on the basis of plasma withdra-
wal), and the other 19 were identified from among the
maternity cohort collection (on the basis of sera with-
drawal). All individuals in the county of Västerbotten
are continuously invited to donate blood samples to the
Medical Biobank, the plasma from which is stored at
-80°C in a biorepository, and blood samples are drawn
from all pregnant women with the sera stored at -20°C.
Full details of the conditions for recruitment and the
collection and storage of blood samples have been
described previously [10].
A nested 1:4 case-control study was undertaken with
the 38 identified individuals, referred to hereinafter as
“presymptomatic” individuals, and randomly selected
controls (n = 152) from the same population-based
cohorts matched for sex, age and date of blood sampling
as well as area of residence. The mean age at the time
blood sampling of the individuals who subsequently
developed SLE was 36.9 years (age range, 16.8 to 60.2
years) and that of the matched controls was 36.7 years
(age range, 17.8 to 62.3 years). The patients’ ages at the
time of sampling, the time predating the onset of symp-
toms and diagnosis and the time after sampling until
the onset of symptoms are presented in Table 1 for
both the Medical Biobank (stratified by sex) and mater-
nity cohorts.
Samples from three prepatients and six controls, all
from the maternity cohort, were no longer available;
that is, insufficient sera were available for analysis. The
frequencies of nonsmokers, ex-smokers and current
smokers among the presymptomatic patients were
47.2%, 26.3% and 26.3%, respectively. The equivalent
data are not available for the controls.
The study was approved by the Regional Ethics Com-
mittee of the University Hospital in Umeå, and all parti-
cipants gave their written informed consent.
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Autoantibodies against Ro/SSA (52 and 60 kDa), La/
SSB, dsDNA, ribonucleoprotein (RNP), Smith (Sm), his-
tidyl-tRNA synthetase (Jo-1), scleroderma (Scl-70), cen-
tromere protein B and histones in plasma from 19
presymptomatic individuals and matched controls (n =
76) (Medical Biobank), in sera from 16 presymptomatic
individuals and matched controls (n =7 6 )( m a t e r n i t y
cohort) and in sera from SLE patients (n = 38) were col-
lected during the disease. All autoantibodies were
detected using the multiplex AtheNA Multi-Lyte ANA
II Plus Test (Zeuss Scientific, Raritan, NJ, USA) and
analysed on a Bio-Plex Array Reader (Luminex
200 Lab-
map™ s y s t e m ;L u m i n e xC o r p . ,A u s t i n ,T X ,U S A ) .T h e
cutoff level for a positive value for each autoantibody
recommended by the manufacturer was used, that is,
120 AU/ml for all analytes. Analyses of ANAs were per-
formed by indirect immunofluorescence on human epi-
dermal cell 2 (HEp-2 cells) slides (Immunoconcept,
Sacramento, CA, USA) using 1:100 diluted samples.
Analyses of the autoantibodies (ANAs, anti-dsDNA,
anti-Ro/SSA, anti-La/SSB, anti-Sm, anti-RNP, anti-Jo-1,
anti-Scl-70, anti-centromere protein B and antihistone)
in the sera of the patients at diagnosis were also under-
taken by the routine clinical immunology laboratory at
the University Hospital. ANAs were analysed by indirect
immunofluorescence with HEp-2 cells or rat tissue (in
house), anti-dsDNA was analysed on Crithidia luciliae-
coated slides (Immunoconcept) and the other autoanti-
bodies were analysed either by enzyme-linked immuno-
sorbent assay or by immunoblot assay.
Statistics
Statistical calculations were performed using SPSS for
Windows version 17.0 software (SPSS, Inc., Chicago, IL,
USA). Continuous data were compared by nonpara-
metric analyses with the Wilcoxon signed-rank test for
matched pairs (prepatients versus SLE patients) and
conditional logistic regression analyses (prepatients ver-
sus controls). The relationships between categorical data
(positive versus negative) were compared using c
2 analy-
sis or Fisher’s exact test as appropriate. All P values are
two-sided, and P ≤ 0.05 was considered statistical signif-
icant. P values corrected for the number of comparisons
made outside the hypothesis are presented as P cor-
rected (Pc).
Results
Analyses in presymptomatic individuals and controls
Of the 35 presymptomatic individuals whose blood sam-
ples were available, 22 (63%) had any detectable autoan-
tibodies in their blood before the onset of symptoms,
that is, predating disease by a median of 4.2 years
(range, 2.1 to 7.9 years). Ten of these patients expressed
one autoantibody, whilst 12 others had two or more
autoantibodies (range, from two to seven). The sensitiv-
ity was highest for ANAs at 45.7% with a specificity of
95%, followed by anti-dsDNA and anti-Ro/SSA antibo-
dies, both with a sensitivity of 20% but with specificities
of 98.7% and 97.4%, respectively (Table 2). The sensitiv-
ities for the other autoantibodies were between 14.3%
and 2.9% at 98% to 100% specificity levels (Table 2).
The odds ratio (ORs) for predicting the development of
SLE were highest for anti-dsDNA at 18.13 (95% confi-
dence interval (95% CI), 3.58 to 91.84), followed by
ANAs at 11.5 (95% CI, 4.54 to 28.87) and anti-Ro/SSA
antibodies at 8.94 (95% CI, 2.45 to 32.58). The ORs for
the other antibodies were between 9.36 and 4.29,
although the number of positive individuals was low,
that is, up to five. The likelihood ratio (LR) was highest
for anti-dsDNA antibodies at 15.38, followed by ANAs
with a LR of 9.14.
T h ea u t o a n t i b o d yt y p et oa p p e a rf i r s tb e f o r et h eo n s e t
of symptoms was anti-Ro/SSA antibody at a mean (±SD)
of 6.6 ± 2.5 years. Anti-RNP and antihistones also
appeared early at means (±SD) of 5.9 ± 2.5 years and 5.0
± 1.5 years, respectively, although the number of positive
individuals with each antibody was small, that is, four
and five, respectively. The autoantibodies first detectable
closest to disease onset were anti-centromere protein B
at 0.2 years, anti-Sm at 0.7 years and anti-Scl-70 at a
mean (±SD) of 1.4 ± 0.6 years (Table 3). The number of
individuals expressing autoantibodies increased the closer
they got to the onset of symptoms, that is, 12 (63%) of 19
individuals had autoantibodies present <5 years before
disease onset compared with 8 (50%) of 16 individuals
who had autoantibodies present ≥5 years before disease
onset. The number of autoantibodies per individual also
Table 1 Age at sampling, at onset of symptoms and disease onset and predating time presented as median values
(Q1, Q3)
Medical Biobank
Patient characteristics Females (n = 16) Males (n = 3) Maternity cohort (n = 19)
Median age at sampling 50.1 (40.2, 52.3) 50.2 (49.2, 60.1) 24.7 (21.7, 29.0)
Median age at symptom onset 52.0 (46.8, 61.2) 52.3 (51.0, 62.1) 31.7 (26.5,39.1)
Median age at diagnosis 53.5 (48.0, 62.7) 52.8 (51.1, 63.1) 37.8 (30.2, 43.1)
Predating time between sampling and symptom onset 5.28 (1.44, 7.88) 2.03 (1.74, 2.06) 6.74 (3.0, 9.24)
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symptoms, particularly during the last 3 years before dis-
ease onset; however, this change did not reach statistical
significance. The accumulated number of individuals
who were positive for each antibody before any symp-
toms of disease and after disease onset is illustrated in
Figure 1. In the maternity cohort, 37.5% had autoantibo-
dies predating disease, compared with 94% in females
and 100% in males from the Medical Biobank cohort.
The number of positive autoantibodies increased with
age at the time of blood sampling (P = 0.001, Pc <
0.01). Those individuals who had autoantibodies predat-
ing disease onset were older both at the time of blood
sampling and at the onset of symptoms (42.8 versus
28.3 years and 49.3 versus 36.0 years; P = 0.002, Pc<
0.05, and P = 0.005, Pc < 0.05, respectively). The interval
between blood sampling and the onset of clinical symp-
toms was shorter than it was for those who had no
autoantibodies in their presymptom sample; however,
this finding was not statistically significantly different
(mean 5.2 years versus 6.3 years before symptom onset).
Analyses in presymptomatic individuals and at diagnosis
of SLE
The mean number of autoantibodies present in predis-
ease individuals was 1.4 and increased after disease onset
to 3.1 (P < 0.0005). In the autoantibody positive presymp-
tomatic individuals (n = 22), the mean number of autoan-
tibodies was 2.2 before and 3.3 after a diagnosis of SLE (P
<0 . 0 1 6 ,Pc < 0.1), whilst among the antibody-negative
prepatients (n = 13), the mean number of autoantibodies
after diagnosis was 2.8 (P < 0.002, Pc < 0.05).
The autoantibodies present in relation to symptoms at
the onset of disease are presented in Table 4. The
patients with serositis (n = 6; four females and two of
three males) at the onset of symptoms had higher fre-
quencies of autoantibodies than did those with arthritis
(n = 20; one of three males) and skin manifestations
Table 2 Sensitivity and specificity of autoantibodies before onset of disease symptoms in individuals who later
developed SLE
a
Presymptomatic individuals
Autoantibodies Sensitivity, n (%) Specificity n (%) Controls, n (%) OR 95% CI P value
b LR
ANA 16 (45.7)*** 95.0 10 (6.7) 11.5 4.54 to 28.87 <0.0001 9.14
dsDNA 7 (20.0)*** 98.7 2 (1.4) 18.13 3.58 to 91.84 <0.0001 15.38
Ro/SSA 7 (20.0)*** 97.4 4 (2.7) 8.94 2.45 to 32.58 <0.0001 5.56
Histone 5 (14.3)** 98.0 3 (2.0) 8.06 1.83 to 35.54 <0.001 7.15
RNP 4 (11.4)** 98.7 2 (1.4) 9.36 1.64 to 53.36 <0.01 8.77
La/SSB 3 (8.6)** 100 0
Jo-1 3 (8.6)* 98.7 2 (1.4) 6.80 1.09 to 42.36 <0.05 6.62
Scl-70 2 (5.7) 99.3 1 (0.7) 8.85 0.78 to 100.51 ns 8.0
Sm 1 (2.9) 100 0
Centromere protein B (2.9) 98.7 1 (0.7) 4.29 0.26 to 70.39 ns 1.54
a95% CI, 95% confidence interval;
bP values were determined by using c
2 test or Fisher’s exact test as appropriate. . * = p < 0.05, **= p < 0.01, ***= p < 0.001
ANA, antinuclear antibody; dsDNA, double-stranded DNA; Jo-1, anti-histidyl-tRNA synthetase antibody; La/SSB, anti-Sjögren’s syndrome antigen B; LR, positive
likelihood value; ns, not significant; OR, odds ratio; RNP, ribonucleoprotein; Ro/SSA, anti-Sjögren’s syndrome antigen A; Scl-70, scleroderma 70; Sm, Smith.
Table 3 Duration in years of the various antibodies preceding the onset of symptoms and disease
a
Antibody Number of positive test
results
Interval between positive test and onset of
symptoms, mean (SD)
Interval between positive test and
diagnosis, mean (SD)
Ro/SSA 7 6.6 (2.5) 8.1 (2.3)
RNP 4 5.9 (2.5) 7.5 (2.5)
Histones 5 5.0 (1.5) 6.5 (1.9)
ANA 16 4.1 (0.8) 7.5 (1.2)
La/SSB 3 4.0 (1.0) 7.0 (0.6)
dsDNA 7 3.6 (1.2) 6.6 (2.0)
Jo-1 3 2.4 (1.1) 3.1 (1.1)
Scl-70 2 1.4 (0.6) 2.1 (0.9)
Sm 1 0.7 1.1
Centromere
protein B
1 0.2 6.6
ANA, antinuclear antibody;
aRo/SSA, anti-Sjögren’s syndrome antigen A; dsDNA, double-stranded DNA; Jo-1, anti-histidyl-tRNA synthetase antibody; La/SSB, anti-
Sjögren’s syndrome antigen B; RNP, ribonucleoprotein; Scl-70, scleroderma 70; SD, standard deviation; Sm, Smith.
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bodies among these patients being 2.5, 1.7 and 0.9,
respectively. However, the time interval predating dis-
ease was shorter for those with primary symptoms such
as serositis (median, 1.9 years) in comparison with those
with arthritis (6.7 years) and skin manifestations (4.2
years). In one individual, the symptom preceding the
onset of disease was nephritis without any autoantibo-
dies detectable when analysed 3.7 years before disease
onset, although at onset the patient was ANA- and anti-
dsDNA-antibody-positive. There was no association
between smoking and autoantibody formation in either
the number of autoantibody-positive individuals or the
number of autoantibodies present.
Figure 1 Graph showing the accumulated number of positive individuals for each antibody. Shown as the percentage predating disease
onset in years and after diagnosis of the disease. ANA, antinuclear antibody; SSA, Sjögren’s syndrome antigen A; SSB, Sjögren’s syndrome
antigen B; dsDNA, double-stranded DNA; RNP, ribonucleoprotein; histon, histone.
Table 4 Autoantibodies predating onset of SLE and presenting symptoms at disease onset
a
Antibody Arthritis
(n = 19)
Skin manifestation
(n = 11)
Serositis
(n =6 )
Haematologic disorder
(n =2 )
Neurologic disorder
(n =1 )
Renal disorder
(n =1 )
ANA 9 4 4 1 0 0
dsDNA 5 1 2 0 0 0
Ro/SSA 3 2 2 0 1 0
Histone 4 1 1 0 0 0
RNP 4 0 1 0 0 0
La/SSB 2 1 0 0 0 0
Jo-1 2 0 2 0 0 0
Scl-70 2 0 1 0 0 0
Sm 1 0 1 0 0 0
Mean number of
antibodies/patient
1.6 0.9 2.5
No antibody 7 5 2 1 0 1
aANA, antinuclear antibody; dsDNA, double-stranded DNA; Jo-1, anti-histidyl-tRNA synthetase antibody; La/SSB, anti-Sjögren’s syndrome antigen B; RNP,
ribonucleoprotein; Ro/SSA, anti-Sjögren’s syndrome antigen A; Scl-70, scleroderma 70; Sm, Smith.
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development of the disease, the concentrations of six of
the autoantibodies that were positive in presymptomatic
patients, namely, the autoantibodies anti-Jo-1 (n =3 ) ,
anti-Scl-70 (n =2 ) ,a n t i - R N P( n =2 ) ,a n t i h i s t o n e( n =
2), anti-Ro/SSA (n = 1) and anti-centromere protein B
(n = 1), decreased to below the cutoff values on the
basis of either the multiplex detection kit or routine
laboratory protocols.
Discussion
In this study, we have shown that autoantibody seropo-
sitivity preceded the onset of SLE, as defined by ACR
criteria, by years. In those individuals who subsequently
developed SLE, the number of autoantibodies increased
gradually. This could suggest a gradual pathogenic pro-
cess over a long period. Our results are consistent with
data reported in other prospective studies of asympto-
matic individuals who later developed SLE [3], rheuma-
toid arthritis (RA) [10,11] or other autoimmune diseases
[9]. ANAs were in line with the results presented by
Arbuckle et al. [3] in that the most prevalent autoanti-
bodies were found in individuals before the onset of
symptoms. However, the frequency of the different auto-
antibodies predating SLE was lower in our study than
the frequencies reported by others [3,20]. This could be
explained by the longer time predating the onset of dis-
ease relative to the lower number of samples.
Furthermore, one must consider the ethnic back-
ground of the different patient cohorts. All of the indivi-
duals included in the present study were from northern
Sweden, whilst in the two other studies cited [3,20], 62%
were black in both studies, with only 29% and 26%,
respectively, being of European background. Anti-
extractable nuclear antigen (anti-ENA) antibodies have
been found to be more common in Afro-Caribbean and
African-American populations than in Caucasians
[21-23]. Conversely, the importance of ethnic differences
in relation to autoantibodies was not confirmed in
another study [24].
Another possible explanation for the lower frequency
of detectable autoantibodies in the individuals studied
here is that one-half of the samples were sera from
pregnant women, in whom the frequency of autoantibo-
dies is known to generally be lower. Also, these donors
were younger at the time of blood sampling, and conse-
quently the time interval before disease onset for most
of the individuals was longer. The samples from the
maternity cohort were taken early in pregnancy, which
can be of importance when considering that these pre-
symptomatic individuals had a lower prevalence of auto-
antibodies than the remainder of the patients and also
that pregnancy is, partially at least, an immunosuppres-
sive state. These individuals were also younger at the
time of the collection of blood samples, when the symp-
toms started and when the diagnosis of SLE was con-
firmed. Their samples had also been stored frozen for a
longer time, which should be considered as a factor that
could interfere with the analyses. After the diagnosis
was established, these patients had marginally fewer
autoantibodies than the other patients, although not sig-
nificantly so. It has long been suggested that autoanti-
body formation increases with age [25,26] as was found
in the present study.
In line with the other studies [3,20], anti-Ro/SSA
antibodies were the first to be detected and preceded
the onset of SLE by several years, whilst anti-Sm and
anti-centromere protein B antibodies appeared closer
to the onset of clinical symptoms. Also, as described
by Arbuckle et al. [3], anti-dsDNA antibodies
appeared at an intermediate time point. Our results
differ from those of Arbuckle et al. in the way that
ANAs appeared at an intermediate point relative to
the onset of clinical symptoms and that anti-La/SSB
antibodies appeared closer to the onset of symptoms.
This finding is consistent with the hypothesis of a
progression due to epitope spreading as previously
described both in animal models and in SLE patients
[27-29].
The individuals who had serositis as the first symptom
had more autoantibodies and a shorter time interval
between the positive blood sample and disease onset
than other onset symptoms, suggesting that a more ser-
ious manifestation in the beginning of the disease is
associated with faster disease development and more
pronounced epitope spread i n g .H o w e v e r ,w ew e r e
unable to show a significant increase in the number of
autoantibodies preceding symptom or disease onset, but
after the onset of disease the number of antibodies
increased significantly.
The OR for predicting SLE was highest for anti-
dsDNA antibodies, followed by ANAs and the other
autoantibodies with lower ORs, but all were within the
95% CI for the OR of anti-dsDNA antibodies. The num-
ber of individuals positive for most of the other antibo-
dies was small: between two and five.
In this study, 6.7% of the population based controls
were positive for ANAs at a preset specificity of 95%.
However, ANA positivity alone in healthy individuals
was not regarded as a good predictor of developing con-
nective tissue disease [30,31]. Two controls were posi-
tive for anti-Jo-1 antibodies and one was positive for
anti-Scl-70 antibodies, which are rare autoantibodies.
However, because of the limited amounts of sera and
plasma available from the Medical Biobank, we were not
able to undertake any confirmatory analyses for anti-
ENA or anti-dsDNA antibodies using alternative techni-
ques, which would have been desirable.
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autoantigens present in the cell nuclei visualised by
ANA analysis using immunofluorescence. In the
nucleus, there are many antigens other than ENA or
chromatin that cannot be detected by specific methods
today. Comparison between multiple assays for autoanti-
body detection in SLE has shown variable frequency of,
for example, Scl-70, with higher frequencies published
using the same assay as we used in this study, suggest-
ing a too low cutoff value, at least for Scl-70 [32,33].
In this study, we could not find any difference in auto-
antibody formation between smokers and nonsmokers.
A significantly higher risk of dsDNA seropositivity was
found in current smokers compared with those who had
never smoked in a previous study of SLE patients [34].
Smoking has been suggested as an environmental factor
involved in the pathogenic development of autoantibo-
dies to citrullinated proteins and rheumatoid factor in
patients with RA [35].
This study is limited by the availability of stored sam-
ples and by not having several samples collected from
the same individual before the onset of symptoms. How-
ever, these individuals were patients attending one
clinic, where they are followed regularly. The controls
used in this study were sampled at the same time as the
patients, and their samples were collected, stored and
analysed in the same way.
We have also used a newly introduced multiplex tech-
nique, which is similar to that used by Heinlen et al.
[20], thereby making comparison with the previous pub-
lication by Arbuckle et al. [3] more difficult. The multi-
plex technology is very suitable, since the amount of
serum or plasma required is very small relative to the
number of analytes it is possible to detect in any given
sample. This is of special benefit when analysing stored
serum samples from biobanks, where the volumes stored
are limited.
Conclusions
On the basis of this study, we conclude that autoantibo-
dies against nuclear antigens can be detected several
years before the onset of symptoms and SLE diagnosis
in individuals who subsequently develop SLE. The high-
est sensitivities were for ANA, Ro/SSA and dsDNA, and
anti-dsDNA antibodies had the highest predictive value
for SLE. Antibodies against Ro/SSA were the first auto-
antibodies detected. Individuals who had serositis as the
first symptom had more autoantibodies and a shorter
time interval between the positive blood sample and dis-
ease onset than other onset symptoms, suggesting that
more serious disease manifestation in the beginning of
the disease is associated with faster disease development
and more pronounced epitope spreading.
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